Back to top

Image: Bigstock

Top Ranked Momentum Stocks to Buy for March 19th

Read MoreHide Full Article

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, March 19th:

The Clorox Company (CLX - Free Report) : This manufacturer of consumer and professional products has a Zacks Rank #2 (Buy) and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2% over the last 60 days.

Clorox’s shares gained 20.1% over the last one month above the S&P 500’s decrease of 28.9%. The company possesses a Momentum Score of A.

Campbell Soup Company (CPB - Free Report) : This manufacturer of food and beverage products has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 2.8% over the last 60 days.

Campbell Soup’s shares gained 11.7% over the last one month. The company possesses a Momentum Score of A.

Vaxart, Inc. (VXRT - Free Report) : This clinical-stage company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 86.4% over the last 60 days.

Vaxart’s shares gained 75.5% over the last one month. The company possesses a Momentum Score of B.

Novavax, Inc. (NVAX - Free Report) : This late-stage biotechnology company has a Zacks Rank #2 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 24.4% over the last 60 days.

Novavax’s shares gained 18.9% over the last one month. The company possesses a Momentum Score of B.

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +50%, +83% and +164% in as little as 2 months. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>

Published in